BIO announces presenting companies for 2012 conference.

Press Release Summary:



Scheduled for Feb 13-14, BIO CEO and Investor Conference focuses solely on publicly-traded biotechnology companies and provides platform for companies to present their story to investors, analysts, and potential corporate partners. Presenting companies consist of mid- to large-cap established companies, which typically have a clinical stage program centered on therapeutics, molecular diagnostics, or platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst.



Original Press Release:



BIO Announces Presenting Companies for 14th Annual BIO CEO & Investor Conference



BIO CEO & Investor Conference will be held February 13 - 14 in New York City, NY

BIO CEO & Investor Conference 2012

WASHINGTON--The Biotechnology Industry Organization (BIO) today announced the initial selection of presenting companies for the 14th Annual BIO CEO & Investor Conference to be held February 13 - 14, 2012 in New York City.

"As the largest independent investor conference focused solely on publicly-traded biotechnology companies, this event provides an ideal platform for companies to present their story to investors, analysts, and potential corporate partners," said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO.

Presenting companies are hand-selected for the event, and consist of a selection of mid- to large-cap established public companies from around the globe, which typically have a clinical stage program centered on therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst. A total of 140 companies will present their story at the conference in February.

The CEO & Investor Conference provides a forum for investors, industry analysts and senior biotechnology executives to shape the future investment landscape of the industry. Investors attend to network with management from the top biotechnology companies, evaluate fresh investment opportunities, attend candid panel discussions and get an overview of the industry and key issues affecting investments.

As of today, the following companies are scheduled to present at this year's conference:

o ACADIA Pharmaceuticals Inc., ACAD

o Achillion Pharmaceuticals, Inc., ACHN

o Acorda Therapeutics, Inc., ACOR

o Addex Pharmaceuticals, SWF:ADXN

o Advaxis Inc., ADXS

o Aegerion Pharmaceuticals, Inc., AEGR

o Affymax, Inc., AFFY

o Agenus Inc., AGEN

o Alkermes plc , ALKS

o Allon Therapeutics Inc. , TSE:NPC

o Antisense Therapeutics Limited, ASX:ANP

o Aradigm Corporation, ARDM

o Arena Pharmaceuticals, Inc., ARNA

o Astex Pharmaceuticals, ASTX

o AVI BioPharma, AVII

o Bavarian Nordic A/S, CPH:BAVA

o BioLineRX, Ltd., TLV:BLRX

o BioSante Pharmaceuticals, Inc., BPAX

o Biotron Limited, ASX:BIT

o Cerus Corporation, CERS

o Compugen, CGEN

o Curis Inc., CRIS

o Cyclacel Pharmaceuticals, Inc., CYCC

o Cytokinetics, Inc., CYTK

o CytRx Corporation, CYTR

o DARA BioSciences, Inc., DARA

o DURECT Corporation, DRRX

o Epigenomics AG, ETR:ECX

o Galena Biopharma, GALE

o GENFIT, EPA:ALGFT

o GenVec, Inc., GNVC

o Geron Corporation, GERN

o Idenix Pharmaceuticals, Inc., IDIX

o Idera Pharmaceuticals, Inc., IDRA

o ImmunoCellular Therapeutics, Ltd., IMUC

o ImmunoGen, Inc., IMGN

o Inovio Pharmaceuticals, Inc., INO

o Interleukin Genetics, ILIU

o Karo Bio AB, STO:KARO

o KineMed, Inc.

o Lexicon Pharmaceuticals Inc., LXRX

o The Michael J. Fox Foundation for Parkinson's Research - Patient Advocacy Group

o Momenta Pharmaceuticals, Inc., MNTA

o Neoprobe Corporation, NEOP

o NeoStem, Inc., NBS

o Neovacs SA, EPA:ALNEV

o Novelos Therapeutics, Inc., NVLT

o NuPathe Inc., PATH

o OncoGenex Pharmaceuticals Inc., OGXI

o Oncothyreon, ONTY

o Opexa Therapeutics, Inc., OPXA

o Oragenics Inc., ORNI

o Orexigen Therapeutics, Inc., OREX

o PDL BioPharma, Inc., PDLI

o PolyMedix Inc., PYMX

o Repligen Corporation, RGEN

o Repros Therapeutics Inc., RPRX

o Resverlogix Corp., RVX

o Rigel Pharmaceuticals, Inc., RIGL

o SciClone Pharmaceuticals, Inc., SCLN

o StemCells, Inc., STEM

o Sunesis Pharmaceuticals, Inc., SNSS

o Synergy Pharmaceuticals, Inc., SGYP

o Targacept, Inc., TRGT

o Tengion, Inc., TNGN

o Topotarget A/S, CPH:TOPO

o Transcept Pharmaceuticals, Inc., TSPT

o Tranzyme, Inc., TZYM

o Trius Therapeutics, TSRX

o Unigene Laboratories, Inc., UGNE

o VirtualScopics, VSCP

o ZIOPHARM Oncology, Inc., ZIOP

Check back often as new presenters are continuously being added. If you are interested in becoming a presenter, please submit an application here.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, a multiblog platform and monthly newsletter that aims to create an online biotech community where the the industry can connect to discuss the latest news. Subscribe to BIOtechNOW.

For more information:

Visit www.bio.org

Follow us on Twitter @IAmBiotech

Join us on LinkedIn/MyBio

Become a fan at facebook.com/IAmBiotech

All Topics